Coherex Medical is focused on the development of devices that address structural heart disease. Our lead product is the WAVECREST Left Atrial Appendage Occlusion System. The WAVECREST is a Left Atrial Appendage (LAA) occlusion device that is designed to help reduce the incidence of stroke originating in the left atrial appendage in patients suffering from atrial fibrillation.
The Wavecrest LAA device offers several advantages over existing products by separating the occlusion and anchoring features and utilizing non-thrombogenic materials in the occluder. The device has completed initial preclinical testing and first in man studies in late 2010. Enrollment began in the WAVECREST I phase 2 clinical study in March, 2011. Coherex, in collaboration with investigators from the WAVECREST I clinical study. has recently improved the WaveCrest device to simplify ease of use and placement. Enrollment in the WAVECREST I study is currently ongoing. CE mark for this device is anticipated in 2013.
The WaveCrest device is currently available for investigational use outside the US only. The WaveCrest device is not available for investigational use or commercial distribution in the US at this time.
Coherex Medical - Dedicated to finding Structural Heart Solutions and evolving clinical therapies to address heart disease.
Thank you for visiting the Coherex USA website. This website is intended for the residents of the USA only.
This USA site may contain information on products or uses of those products that are not approved in other countries or regions.
If you are a resident of a country other than the USA, please return to www.coherex.com and choose the Coherex OUS website.
Notice: The Coherex FlatStent EF PFO Closure System is not available for investigational use or for commercial distribution at this time in the U.S.A.
